Posts Tagged ‘Breast Cancer’
Critical Role of Novel Gene Marker HOTAIR in Severe Breast Cancer Type
A latest study conducted by scientists from Stanford Univ. School of Medicine has found that females with breast cancer having elevated levels of tumor expression of a certain genetic marker HOTAIR had a considerably greater likelihood of death due to the disease as compared to those with comparatively normal levels. Study findings have shown promise for patients with severe breast cancer type.
Howard Chang, senior author of the study and an associate Prof. of dermatology, Stanford Caner Center explained that dysregulation of a lately identified form of RNA, HOTAIR occurs in breast cancer leading to it driving the tumour cells into metastasis and worsening likelihood of recovery in such women.
Chang along with his associates have been researching HOTAIR (HOX antisense intergenic RNA) for many [...]
April 23rd, 2010 |
Breast Cancer
Claudia Schiffer, Sienna Miller, Kylie Minogue in new breast cancer awareness campaign
After having bravely fought and beaten cancer four years ago, singer Kylie Minogue is now proactively raising breast cancer awareness in a spectacular new-fangled campaign.
The forty-one-year old Minogue would be peeling off and donning zilch except for a dazzling smile and silken piece of fabric bearing Fashion Targets Breast Cancer emblem over it in an eye-catching picture captured by famous snapper Mario Testino.
Kylie’s association in the breast cancer awareness campaign has come almost 5 years subsequent to her diagnosis of breast cancer during May 2005. Subsequent to have undergone a year’s treatment course that entailed partial mastectomy for removal of a malignant tumor, chemotherapy and radiotherapy 8 months anon, the pop diva eventually did manage to achieve remission in 2006. [...]
April 7th, 2010 |
Breast Cancer, News
Aspirin – Top FAQs on Breast Cancer Combating Effects
A new-fangled study has shown that aspirin has anti-cancer outcomes. The recent of such studies indicate that subsequent to being successfully treated for breast cancer, women that took aspirin on a regular basis had a considerable plummet in risk of facing fatality due to recurring cancer.
In the light of this latest revelation, how would it translate for individuals undergoing cancer treatment and what would it mean for those apprehensive regarding their risk of developing cancer.
Explained below are answers to several of the commonly posed queries regarding aspirin and breast cancer.
Is breast cancer survival truly improved due to aspirin intake?
Solely a clinical study wherein an arbitrarily allocated treatment is analysed against a dormant placebo could help in proving whether a treatment [...]
March 1st, 2010 |
Breast Cancer, News
Cowden syndrome
Cowden syndrome (CS) is an atypical heritable condition typified by several non-cancerous nodules known as hamartomas. Cowden syndrome sufferers additionally are at heightened risk of particular forms of cancer.
CS is believed to be rare, though it is possibly under-detected. It is approximated that CS affects 1 in every two lakh people.
CS is typified by increased chances of developing both non-cancerous and cancerous tumors inflicting breast, thyroid and endometrial lining of the uterus.
Cowden syndrome symptoms
Key signs and symptoms of CS are explicated below:
Trichilemmomas – skin tags.
Papillomatous papules.
Macrocephaly – more than average head circumference or enlarged head.
Breast fibrocystic disease – A condition typified by existence of malignant breast tissues.
Greater risk [...]
February 11th, 2010 |
Tumor
Breast Cancer Oncotype DX Testing – Positively Impacting Chemotherapy Treatment Choices
A multi-gene test that forecasts if preliminary staging breast cancer patients would be benefitted due to chemotherapy is majorly impacting treatment verdicts taken by both the patient and physicians comparably.
The multi-gene test known as Oncotype DX manufactured by Genomic Health Industries lead to doctors changing their treatment suggestions in about thirty-two percent of the cases whereas twenty-seven percent of the patients modified their treatment choices. In majority of these cases, the amendment in decision was observed from both the doctors as well as the patient’s end to steer clear from undergoing chemotherapy.
The Oncotype DX multi-gene test evaluates twenty-one genes from a neoplasm sample for ascertaining how progressive the neoplasms were. An analysis score lying from zero [...]
January 14th, 2010 |
Breast Cancer
Elastrography Lowers Redundant Breast Biopsies
According to an in-progress study presented during the yearly congregation of the Radiological Society of North America (RSNA) showed that elastography is an effectual, expedient system that when included to breast ultrasound aids in detection of cancerous breast lesions from benign outcomes.
When the outcome of mammography gives dubious findings, doctors mostly employ ultrasound to attain added information. On the other hand ultrasound has the possibility to lead to additional biopsies due to its comparatively squat specificity or incapability to precisely differentiate cancerous lesions from benign lesions. According to the American Cancer Society about eighty percent of breast lesions that underwent biopsies turned out to be benign in nature.
Stamatia V. Destounis, M.D., the lead author [...]
December 7th, 2009 |
Breast Cancer
Study Indicates No Overuse Of Mastectomies In Breast Cancer Treatments
There have been growing fears about mastectomy being overly employed as a treatment option for breast cancer. A study conducted that was printed in the 14th October edition of JAMA, carried out an analysis of about two thousand women suggested that breast-conservation surgery was undertaken as the initial treatment in nearly 75% of those analysed.
Monica Morrow, M.D., from the Memorial Sloan-Kettering Cancer Center, New York did the presentation of the study findings at the JAMA media update in Chicago. She stated that the rising worries of mastectomy being used on patients having breast cancer have increased in past twenty years. BCS or breast conservation surgery has been employed by few as a quality measure. In spite of a noticeable rise in BCS, fears continue about the overtreatment with [...]
December 2nd, 2009 |
Breast Cancer
Potent Blend Of Treatments Combats Breast Tumors
At the conclusion of the decade old, coast-to-coast survey on women having a rare type of breast cancer, Richard J. Barth Jr., M.D., and three associate researchers are composing the case for a particular blend of treatments for halting the tumors prior to metastasis.
In the Aug-09 edition of the Annals of Surgical Oncology, Barth, an associate professor of surgery at Dartmouth Medical School (DMS) and his associates along with Wendy Wells, M.D. – a professor of pathology in DMS suggest employing adjunct radiotherapy on those patients that underwent breast-preservation surgery for controlling borderline malignant and malignant phyllodes tumors.
The follow-ups done on the improvement in 46 women that were given follow-up radiotherapy in thirty diverse organizations in eighteen states, the [...]
November 30th, 2009 |
Breast Cancer
Biennial Mammography – Analogous Advantages As Yearly Screening But With Lesser Harm
A wide-ranging examination of different mammography screening programmes indicate that screening conducted in a time interval of two years (biennial) of women aged 50-74 years having average risk attained maximum gains of yearly screening, however with lesser harmful effects. The outcomes depict an undisputed agreement of 6 autonomous research sets from varied academic institutions.
These findings are printed in the 17th November 2009 edition of Annals of Internal Medicine.
Scientists at CISNET, the NCI-backed Cancer Intervention and Surveillance Modelling Network, employed independent models for examining twenty screening approaches with varying commencing and halting ages and time intervals. Modelling approximates the lifelong impact (results include advantages and harmful effects) of breast [...]
November 23rd, 2009 |
News
Novel Breast Cancer Treatment Delivering Potent Punch With Combination Therapy
A potent new-fangled breast cancer treatment could be the upshot due to binding one of the novel drugs that hamper cancer’s characteristic uninhibited proliferation with another that obstructs a primal survival method wherein the cancer cells gobble up sections of themselves.
During the Molecular Targets and Cancer Therapeutics International Conference, Boston, the researchers from Medical College of Georgia Cancer Center reported that while they are potent obliterators of some breast cancer cells, novel drugs known as histone deacetylase inhibitors (HDAC inhibitors), additionally augment self-assimilation or autophagy, in enduring, mega-strained cells.
Dr. Kapil Bhalla, Director of the MCG Cancer Center stated that for meeting the energy requirements of proliferation and survival, cancer [...]
November 19th, 2009 |
Breast Cancer

